Proactive Investors - Run By Investors For Investors

Amphion Innovations partner Kromek secures key regulatory approval from EU

Amphion Innovations partner Kromek secures key regulatory approval from EU

Amphion Innovations (LON:AMP) said its key partner company Kromek has reached a significant milestone, securing official EU certification to provide colour x-ray liquid detection systems to all European airports.

This means that all airports on the continent are free to buy and implement Kromek’s Bottle Scanner product, marking the first time that airports can purchase tested, approved, and secure technology, allowing them to relax the liquid ban.

The technology is set to loosen up security restrictions for air passengers as it will eliminate the ban on carrying liquids on flights by April 2013.

By April 2011, liquid items bought in transit will be allowed on board, providing the appropriate security measures, such as screening, are in place at the airports concerned.

The results of the European Civil Aviation Conference (ECAC) led trials have proven that the technology is ready to allow the 2011 regulatory deadline to be met by the airports.

Kromek called the achievement a milestone in the company’s history.

“It's a significant milestone for Kromek as the approved listing is vindication that colour x-ray detection has been proven," said chief executive of Kromek Arnab Basu.

“The next generation of X-ray technology has arrived, with a market ready machine that can detect liquid threats.”

Kromek's Bottle Scanner has qualified as a Category B device that has achieved Type 1 and Type 2 100% capability and been officially tested, verified and authorised by ECAC.

The threat from Liquid, Aerosol and Gel (LAG) based explosives became apparent in August 2006 following discovery of a plot to use such devices aboard multiple transatlantic flights.

Kromek also noted that liquid is becoming a common tool for terrorist use, further increasing the relevance of its technology.

“Our groundbreaking technology not only provides products to the airline security market but has the opportunity for development into a range of products for many highly lucrative markets such as medical and industrial fields,” said Basu.

Kromek is seen as the likeliest partner company of Ampion to be the next to become publicly traded.

According to Ampion chief executive Richard Morgan, the earliest the business can be floated would be during the first quarter of 2011, at which point Amphion’s 16% stake should be worth far more than the last valuation of £9 million.

For comparison, Amphion’s current market cap is around £10 million.

Meanwhile, Kromek itself managed to raise £12.3 million in an oversubscribed financing in March this year.

It has also bought California-based NOVA R&D, which added a number of imaging and detection technologies in the chemical, biological, radiological and nuclear space to the enlarged business, as well as what Amphion calls significant commercial relationships.

Investors clearly liked the news, as shares in Amphion rose more than 14% in early trade to 8 pence.

View full AMP profile View Profile

Amphion Innovations Plc Timeline

Related Articles

XTEK: Access latest PPT from Proactive's CEO Sessions
June 18 2017
Philippe Odouard talked growing revenues with investors.
x-ray image
September 04 2017
The radiation detection specialist is expecting revenues to grow by at least 40% this year after spending a couple of years laying the foundations
picture of virtual reality headset
October 24 2017
New shares sold through a book build exercise in about two hours at a tiny discount to the market price to rasie £75mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use